^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

CBT-1 (tetrandrine)

i
Other names: NSC-77037
Associations
Trials
Company:
CBA Pharma
Drug class:
P-glycoprotein inhibitor, Ca2+ channel antagonist, MDR modulator
Associations
Trials
14d
Towards identification of novel inhibitors of EGFR mutants through in-silico approach. (PubMed, Cancer Treat Res Commun)
Among the tested compounds, Tetrandrine, Dauricine, and Olmutinib exhibited robust binding affinities across both wild-type and mutant EGFR configurations, highlighting their potential as effective inhibitors. The integrated approach of combining molecular docking using CB-dock2, ADMET profiling, and Lipinski's rule of five provides a robust framework for preliminary drug candidate screening, potentially accelerating the development of more precise and effective EGFR-targeted therapies. The findings contribute to the growing body of research exploring alternative and more nuanced strategies for inhibiting EGFR-driven oncogenic mechanisms, highlighting the importance of computational methods in identifying novel molecular targets with improved specificity and reduced side effects.
Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR wild-type
|
Olita (olmutinib) • CBT-1 (tetrandrine)
2ms
A clinical trial of Tetrandrine Tablets in combination with Mitotane for the treatment of mitotane-resistant advanced adrenocortical carcinom (ChiCTR2500113189)
P=N/A, N=62, Not yet recruiting, West China Hospital of Sichuan University; West China Hospital of Sichuan University
New trial
|
Lysodren (mitotane) • CBT-1 (tetrandrine)
2ms
New P4 trial
|
CBT-1 (tetrandrine)
2ms
A single-center exploratory study on the efficacy and safety of tetrandrine tablets in the treatment of interstitial lung disease associated with rheumatoid arthritis (ChiCTR2500107574)
P=N/A, N=60, Recruiting, The First Affiliated Hospital of Army Medical University (Southwest Hospital); The First Affiliated Hospital of Army Medical University (Southwest Hos | Not yet recruiting --> Recruiting | Initiation date: Aug 2025 --> Nov 2025
Enrollment open • Trial initiation date
|
Rituxan (rituximab) • cyclophosphamide • prednisone • hydroxychloroquine • tofacitinib • CBT-1 (tetrandrine)
3ms
Dual Potential of Tetrandrine: Antiangiogenic Efficacy and Safety Liabilities Revealed through In Silico, In Vitro, and Zebrafish Models. (PubMed, Food Chem Toxicol)
These findings highlight tetrandrine's dual profile: a promising natural antiangiogenic agent with demonstrable efficacy, yet with significant cardiotoxic and developmental liabilities. This study provides crucial mechanistic insight into both its therapeutic and toxicological actions, establishing a translational foundation for its further development.
Preclinical • Journal
|
EGFR (Epidermal growth factor receptor) • SRPK1 (SRSF Protein Kinase 1)
|
CBT-1 (tetrandrine)
3ms
New P4 trial
|
CBT-1 (tetrandrine)
4ms
Effective components of Coptidis Rhizoma and Cinnamomi Cortex in the treatment of renal cell carcinoma and their mechanism of action. (PubMed, Medicine (Baltimore))
Three components (quercetin, oleic acid, tetrandrine) were highlighted as particularly effective...In conclusion, the therapeutic effect of the HL-RG combination against RCC is primarily mediated by its bioactive components, QUE, OA, and TET. These components regulate the HIF-1 signaling pathway, activating genes involved in the cellular response to hypoxia and modulating the expression of proteins that control glucose metabolism, cell proliferation, and angiogenesis.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • CCND1 (Cyclin D1) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • EGF (Epidermal growth factor) • TGFB1 (Transforming Growth Factor Beta 1) • MMP9 (Matrix metallopeptidase 9) • CAT (Catalase)
|
CBT-1 (tetrandrine)
5ms
Exploring the mechanism of Stephania tetrandra S. Moore in the treatment of cisplatin resistance against ovarian cancer through integration of network pharmacology and molecular docking. (PubMed, Medicine (Baltimore))
Cisplatin resistance is a major contributor to treatment failure in ovarian cancer (OC). Molecular dynamics simulations demonstrated that hesperidin, cissamine and tetrandrine exhibited strong binding affinities toward AURKA, vitamin D receptor, and TTK. Future studies are encouraged to focus on the experimental validation of these compounds and delve deeper into the possible mechanisms of drug resistance, aiming to improve their therapeutic effectiveness and real-world applicability.
Journal
|
BCL2 (B-cell CLL/lymphoma 2) • AURKA (Aurora kinase A) • DNMT1 (DNA methyltransferase 1) • CDK1 (Cyclin-dependent kinase 1) • SMAD7 (SMAD Family Member 7) • TTK (TTK Protein Kinase)
|
cisplatin • CBT-1 (tetrandrine)
5ms
Study on the clinical efficacy and mechanism of tetrandrine in the treatment of patients with lumbar disc herniation (ChiCTR2500108829)
P=N/A, N=64, Not yet recruiting, Affiliated hangzhou first people's hospital, zhejiang university school of medicine; Hangzhou First People's Hospital
New trial
|
CBT-1 (tetrandrine)
5ms
A single-center exploratory study on the efficacy and safety of tetrandrine tablets in the treatment of interstitial lung disease associated with rheumatoid arthritis (ChiCTR2500107574)
P=N/A, N=60, Not yet recruiting, The First Affiliated Hospital of Army Medical University (Southwest Hospital); The First Affiliated Hospital of Army Medical University (Southwest Hos
New trial
|
Rituxan (rituximab) • cyclophosphamide • prednisone • tofacitinib • CBT-1 (tetrandrine)
6ms
Lactoferrin functionalized bovine serum albumin nanoparticles for synergistic chemo-gene therapy of lung cancer: Co-delivery of tetrandrine and miRNA-126. (PubMed, Int J Biol Macromol)
Histopathological findings further verify the superiority of Lf-miRNA-126-Tet@ANPs. These results highlight Lf-miRNA-126-Tet@ANPs as a promising nanoplatform for chemo-gene targeted delivery against lung cancer.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • STAT3 (Signal Transducer And Activator Of Transcription 3)
|
CBT-1 (tetrandrine)
6ms
Investigating C7 modified tetrandrine derivatives for synthesis anti-hepatocellular carcinoma activity and mechanistic insights. (PubMed, Sci Rep)
Notably, compound 15 demonstrated significant antiproliferative activity against all tested cell lines, with IC50 values ranging from 3.28 to 6.16 µM, which is superior to the first-line clinical drug 5-fluorouracil. With its remarkable antitumor activity, excellent synthetic process characteristics, and clear apoptosis-inducing mechanism, compound 15 has emerged as a highly promising clinical candidate. This C-7 modification platform provides a viable path for transforming natural product derivatives into clinical therapies for HCC treatment.
Journal
|
BCL2 (B-cell CLL/lymphoma 2) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • FLT1 (Fms-related tyrosine kinase 1) • PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3)
|
5-fluorouracil • CBT-1 (tetrandrine)